key: cord-0018736-yarw2b10 authors: Horton, Daniel B.; Blum, Michael D.; Burcu, Mehmet title: Real-World Evidence for Assessing Treatment Effectiveness and Safety in Pediatric Populations date: 2021-07-02 journal: J Pediatr DOI: 10.1016/j.jpeds.2021.06.062 sha: 877565c0abf535d80af93b1887479cd805fe46a7 doc_id: 18736 cord_uid: yarw2b10 nan The race for effective treatments against COVID-19 has reminded pediatricians of historical delays that children have faced in drug development and clinical trials. In response to this, legislation and regulations including the Best Pharmaceuticals for Children Act (U.S., 2002), Pediatric Research Equity Act (U.S., 2003), and Pediatric Regulation (E.U., 2007) spurred the conduct of pediatric trials through a combination of incentives and requirements for pharmaceutical companies to increase pediatric drug approvals and evidence supporting treatments for children. Although randomized controlled trials (RCTs) are considered the most rigorous design to demonstrate a drug's efficacy, design alone does not determine whether evidence from the trial is sufficient to establish substantial evidence of effectiveness, as defined in the Kefauver Harris Amendment to the Federal Food, Drug, and Cosmetic Act (U.S., 1962). New indications for treatments are sometimes approved by the FDA and EMA without RCT results, though the reasons for not requiring evidence from RCTs are not always evident 1 . RCTs have many well-known limitations, including high costs, small sample sizes, short follow-up, and questionable generalizability to broader populations, and they cannot answer all the important questions, such as rare but serious harms or long-term safety. Pediatric trials have additional feasibility concerns, relating to smaller potential pools of participants with longer enrollment process; diverse physiology, pathophysiology, and treatment responses across different ages; and practical challenges with recruitment and informed consent. Furthermore, reporting from some mandated pediatric studies has been limited, and pediatric trials and approvals may lag for years despite the legal requirements in place 2 . Despite increases in pediatric labeling, outpatient off-label drug prescribing to children has risen, particularly for conditions without FDA approval at any age 3 . Certain collaborative research networks, such as the Children's Oncology Group, have sufficient size, resources, and capacity to conduct large RCTs with long-term follow-up that address some of the aforementioned limitations of many pediatric trials [4] [5] [6] . Nonetheless, for many conditions, drugs, and outcomes, the challenges are not solved uniformly through more high-quality pediatric RCTs, if feasible. Even in the field of pediatric oncology, certain outcomes (e.g., severe, late-onset cardiomyopathy) are too rare for even large trials to detect and study with any precision 7 . Rigorous research using alternative approaches is also vital to inform pediatric prescribers, caregivers, and patients. Such approaches can help us more fully understand the effects-favorable and unfavorable-that treatments have in children often more efficiently, cheaply, and with greater generalizability than through RCTs. The 21st Century Cures Act (U.S., 2016) places additional focus on uses of data collected outside traditional RCTs (real-world data [RWD]) to generate clinical evidence (real-world evidence [RWE] ) to support regulatory decision-making. RWD encompasses sources such as electronic health records (EHRs), insurance claims, product/disease registries, patient-/caregiverreported outcomes, and wearable/other devices. The framework for FDA's RWE program suggests that RWE may fill evidentiary gaps when traditional RCTs are not feasible, including for populations under-represented in RCTs 8 . RWE may also help assess outcomes/endpoints more valued by patients, families, and payers. Nonetheless, the successful application of RWE to pediatrics requires understanding of both the opportunities and challenges that exist (Table) . J o u r n a l P r e -p r o o f Before treatments are approved for use (initially usually for adults), substantial evidence of efficacy of medical products is required from adequate, well-controlled studies, usually RCTs. However, in certain circumstances, randomization to placebo or alternative treatment is not feasible or ethical, necessitating the use of single-arm trial designs. Real-world benchmark data from real-world external (historical) controls can provide the supplementary contextual data necessary to interpret results from single-arm trials 9 . Multiple medications have received regulatory approvals with supportive RWE derived from real-world external controls, particularly for oncologic and rare disease indications 10 . For example, cerliponase alfa was approved as a treatment for a rare pediatric lysosomal disorder (neuronal ceroid lipofuscinosis type 2 disease) following a single-arm study which used a natural-history RWD external control 11, 12 . As another example of RWE supporting pediatric drug approvals, blinatumomab was approved for pre-cursor B-cell acute lymphoblastic leukemia (ALL) in children based on efficacy data from an open-label phase I/II trial 13 , leveraging historical outcomes data 14, 15 and safety data from a single-arm, open-label (observational) expanded access study 16, 17 . After treatments are approved initially for adults although all use in children is by definition offlabel, RWD can be used to produce much-needed evidence on whether these treatments are safe and effective in children 8 . Where the course and outcomes of disease are sufficiently similar in adults and children, regulatory agencies may conclude that pediatric effectiveness can be extrapolated from well-conducted studies in adults. In such cases, regulatory agencies may combine efficacy data from adults with pediatric pharmacokinetic and safety data for pediatric approval. For example, mepolizumab was approved down to age 6 years as add-on maintenance treatment of patients with severe asthma and an eosinophilic phenotype, based on J o u r n a l P r e -p r o o f pharmacokinetic and safety data in 6-to 11-year-olds and extrapolated efficacy data from RCTs in adolescents and adults 18 . In this case, there was overlap in the clinical presentation of both adult and pediatric severe eosinophilic asthma, consistency in the therapeutic approach, consistency of the mepolizumab mechanism of action, and relevance of the clinical endpoints. When uncertainty remains regarding the extent to which adult data can reasonably apply to children, RWD represent a valuable vehicle for supplying critical missing evidence about treatment effectiveness and safety in routine pediatric care. Even when pediatric RCTs are feasible and ultimately performed, these trials are often limited to narrow populations, short-term exposures (eg, to identify suitable pediatric doses based on pharmacokinetics), and a limited set of outcomes. Such trials leave many unanswered questions about more diverse populations, chronic exposures, and unexamined outcomes, whether delayed, rare, or simply not addressed. Unique safety concerns for children, such as growth and neurodevelopment, may not be addressed fully or sufficiently by RCTs. Careful analyses of RWD and judicious appraisal of RWE provide opportunities to fill in the often large evidentiary gaps in knowledge and examine the uses and effects of treatments (including long-term benefits and risks) in much larger, heterogeneous, and generalizable populations. For instance, a medication approved to treat children with attention deficit/hyperactivity disorder may be shown to significantly improve children's attention and behavior in an RCT setting, but how well does this medication work in underserved, less heavily supervised, or less adherent children? Does the medication affect future scholastic performance? Is it effective and safe when combined with antidepressants, antipsychotics, or hypnotics, or used by children with autism, or taken at doses J o u r n a l P r e -p r o o f not tested in the trials? Countless questions that RCTs are either underpowered or not designed to answer can be addressed by the careful analysis of RWD and judicious appraisal of RWE. Although RWD holds great promise, the elephant in the room is its validity: can we really trust pediatric RWD to generate valid answers/evidence to our questions? The answer is, yes, sometimes, and it depends. Just as RCTs may be flawed and biased (e.g., due to differential dropout across treatment groups), pediatric observational research faces a considerable set of unique potential biases and other limitations that must be appropriately recognized and reckoned with if RWE is to be effectively leveraged for regulatory and clinical purposes. Publications using RWE, including from pediatric populations 19 , vary substantially in quality, and their findings must be viewed critically based on their methods. Fortunately, many common limitations are addressable (Table) . Without the powerful benefits of randomization, overcoming bias from confounding represents a major hurdle for observational pediatric research. Adjustment for measured confounders such as age and comorbidities is essential. Nonetheless, unmeasured confounding may arise when key analytic variables are missing, such as gestational age, date of birth (birthyear is suitable for studies of adults but not neonates/young children), weight and height measurements, family history, or measures of disease activity/severity 20 . EHRs may more reliably include these data than claims databases, but many EHRs generally do not originate from closed health care systems and may not capture all treatments and outcomes of interest 21 . Furthermore, EHRs typically record prescribing, which is a giant step farther from a child's mouth than the claims-J o u r n a l P r e -p r o o f based dispensing data. These omissions in EHR data could be important sources of selection or ascertainment bias. When possible and done properly, linking claims and EHR data allows pediatric researchers to bridge the gaps and produce more valid results 22 . Linkage between children's and their parents' records can facilitate ascertainment of useful covariates, such as prenatal exposures, perinatal events, and family history 23 . Metrics of health care utilization (e.g., hospitalization, number of outpatient visits) can also help reduce bias from unmeasured confounders 24 . Doctors treat patients for a reason, and children who receive certain treatments may be fundamentally different from children who receive other treatments, or none at all. To overcome confounding by indication, disease severity, and other factors in observational research, various designs may help reduce bias, including active-comparator designs 25 , self-controlled designs 26 , sibling-controlled designs 27 , or instrumental variable designs 28 (Table) . In a pinch, a little randomization can go a long way: with pragmatic clinical trials, broad inclusion criteria and fitfor-purpose RWD collection can produce valid RWE on treatment effectiveness or safety 29 . As noted in the Framework for FDA's RWE Program, the agency will explore pragmatic approaches and strategies for trials that generate RWE in some capacity, e.g., pragmatic randomized trials integrated into health care systems 8 . Pediatric research using RWE presents additional unique challenges relating to sample size requirements, evaluation of dose-effects, and lack of available, standardized, or validated outcomes (Table) . For example, because of the fragmented nature of US health care delivery, including frequent changes in insurers and settings of care and pediatric-to-adult transitions of J o u r n a l P r e -p r o o f care, pediatric RWD may be limited in duration, greatly restricting one's ability to study longterm outcomes. Under or uninsured children at particularly high risk for adverse outcomes may not show up in insurance-based datasets and may be overlooked in RWE. Populationrepresentative pediatric data (e.g., from Europe) may, nonetheless, have too small populations to study rare outcomes or lack data on populations of interest (e.g., hospitalized neonates). Ultimately, successful use of RWE to improve outcomes and to support regulatory decisionmaking in pediatrics requires skilled understanding to ask appropriate research questions, access to fit-for-purpose data, infrastructure for managing and analyzing the data, and resources (including funding) to conduct and disseminate reproducible and transparent research [30] [31] [32] . Increasingly such successes rely on collaborative, multidisciplinary teams with relevant expertise and on robust engagement of broad stakeholders, including regulators and patients/caregivers. Integration of patients and caregivers into research teams not only provides a valuable source of RWD but can also enhance the relevance, quality, and impact of research. Rises in pediatric medication use, overall and off-label 3 , as well as increasing availability of RWD, provide valuable and novel opportunities to harness RWE and improve children's health. Given the various challenges, RWE is no substitute for RCTs, and vice versa: they are both essential, complementary, sometimes intertwined approaches. Our children deserve nothing less. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014 Completion Rate and Reporting of Mandatory Pediatric Postmarketing Studies Under the US Pediatric Research Equity Act Trends in Off-Label Drug Use in Ambulatory Settings Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Clinical Trial: A Report From the Children's Oncology Group Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity Food and Drug Administration. Framework for FDA's Real-World Evidence Program Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms Trial designs using real-world data: The changing landscape of the regulatory approval process Study of Intraventricular Cerliponase Alfa for CLN2 Disease Food and Drug Administration. FDA approves first treatment for a form of Batten disease Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study Use of Real-World Evidence to Support FDA Approval of Oncology Drugs Food and Drug Administration. mepolizumab (Nucala) Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review Kids Use Medications and Devices Chapter 13: Electronic Health Record Databases Population-level surveillance of congenital heart defects among adolescents and adults in Colorado: Implications of record linkage Linkage methods for connecting children with parents in electronic health record and state public health insurance data. Maternal and child health journal Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics Active-comparator design and new-user design in observational studies Control Yourself: ISPE-Sponsored Guidance in the Application of Self-Controlled Study Designs in Pharmacoepidemiology Translational Epidemiologic Approaches to Understanding the Consequences of Early-Life Exposures A tutorial on the use of instrumental variables in pharmacoepidemiology Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0 Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative